The global market for Long-acting G-CSF was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Granulocyte colony stimulating factor (G-CSF) is a type of growth factor. G-CSF is a drug that’s most often prescribed after chemotherapy. It helps increase white blood cells called neutrophils that protect the patient from infection. Neutrophils are often destroyed during chemotherapy, causing a condition called neutropenia. G-CSF can also increase the number of stem cells before or after a stem cell transplant. Long-acting G-CSF has a long plasma half-life and only needs to be administered once per chemotherapy cycle.

North American market for Long-acting G-CSF is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Long-acting G-CSF is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Long-acting G-CSF in Neoplastic Diseases is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Long-acting G-CSF include Amgen Inc., Pfizer, Sandoz (Novartis), Biocon Biologics Inc., Coherus BioSciences, Inc., Spectrum Pharmaceuticals, Yifan Pharmaceutical, CSPC, Jiangsu Hengrui Medicine, Qilu Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Long-acting G-CSF, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting G-CSF.

The Long-acting G-CSF market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Long-acting G-CSF market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Long-acting G-CSF companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Long-acting G-CSF Market Report

Report Metric	Details
Report Name	Long-acting G-CSF Market
Segment by Type	Pegfilgrastim Filgrastim Biosimilar Others
Segment by Application	Neoplastic Diseases Blood Disorders Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen Inc., Pfizer, Sandoz (Novartis), Biocon Biologics Inc., Coherus BioSciences, Inc., Spectrum Pharmaceuticals, Yifan Pharmaceutical, CSPC, Jiangsu Hengrui Medicine, Qilu Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-acting G-CSF company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Long-acting G-CSF Market report?

Ans: The main players in the Long-acting G-CSF Market are Amgen Inc., Pfizer, Sandoz (Novartis), Biocon Biologics Inc., Coherus BioSciences, Inc., Spectrum Pharmaceuticals, Yifan Pharmaceutical, CSPC, Jiangsu Hengrui Medicine, Qilu Pharmaceutical

What are the Application segmentation covered in the Long-acting G-CSF Market report?

Ans: The Applications covered in the Long-acting G-CSF Market report are Neoplastic Diseases, Blood Disorders, Others

What are the Type segmentation covered in the Long-acting G-CSF Market report?

Ans: The Types covered in the Long-acting G-CSF Market report are Pegfilgrastim, Filgrastim Biosimilar, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Long-acting G-CSF Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Pegfilgrastim

1.2.3 Filgrastim Biosimilar

1.2.4 Others

1.3 Market by Application

1.3.1 Global Long-acting G-CSF Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Neoplastic Diseases

1.3.3 Blood Disorders

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Long-acting G-CSF Market Perspective (2020-2031)

2.2 Global Long-acting G-CSF Growth Trends by Region

2.2.1 Global Long-acting G-CSF Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Long-acting G-CSF Historic Market Size by Region (2020-2025)

2.2.3 Long-acting G-CSF Forecasted Market Size by Region (2026-2031)

2.3 Long-acting G-CSF Market Dynamics

2.3.1 Long-acting G-CSF Industry Trends

2.3.2 Long-acting G-CSF Market Drivers

2.3.3 Long-acting G-CSF Market Challenges

2.3.4 Long-acting G-CSF Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Long-acting G-CSF Players by Revenue

3.1.1 Global Top Long-acting G-CSF Players by Revenue (2020-2025)

3.1.2 Global Long-acting G-CSF Revenue Market Share by Players (2020-2025)

3.2 Global Long-acting G-CSF Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Long-acting G-CSF Revenue

3.4 Global Long-acting G-CSF Market Concentration Ratio

3.4.1 Global Long-acting G-CSF Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Long-acting G-CSF Revenue in 2024

3.5 Global Key Players of Long-acting G-CSF Head office and Area Served

3.6 Global Key Players of Long-acting G-CSF, Product and Application

3.7 Global Key Players of Long-acting G-CSF, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Long-acting G-CSF Breakdown Data by Type

4.1 Global Long-acting G-CSF Historic Market Size by Type (2020-2025)

4.2 Global Long-acting G-CSF Forecasted Market Size by Type (2026-2031)

5 Long-acting G-CSF Breakdown Data by Application

5.1 Global Long-acting G-CSF Historic Market Size by Application (2020-2025)

5.2 Global Long-acting G-CSF Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Long-acting G-CSF Market Size (2020-2031)

6.2 North America Long-acting G-CSF Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Long-acting G-CSF Market Size by Country (2020-2025)

6.4 North America Long-acting G-CSF Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Long-acting G-CSF Market Size (2020-2031)

7.2 Europe Long-acting G-CSF Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Long-acting G-CSF Market Size by Country (2020-2025)

7.4 Europe Long-acting G-CSF Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Long-acting G-CSF Market Size (2020-2031)

8.2 Asia-Pacific Long-acting G-CSF Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Long-acting G-CSF Market Size by Region (2020-2025)

8.4 Asia-Pacific Long-acting G-CSF Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Long-acting G-CSF Market Size (2020-2031)

9.2 Latin America Long-acting G-CSF Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Long-acting G-CSF Market Size by Country (2020-2025)

9.4 Latin America Long-acting G-CSF Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Long-acting G-CSF Market Size (2020-2031)

10.2 Middle East & Africa Long-acting G-CSF Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Long-acting G-CSF Market Size by Country (2020-2025)

10.4 Middle East & Africa Long-acting G-CSF Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Amgen Inc.

11.1.1 Amgen Inc. Company Details

11.1.2 Amgen Inc. Business Overview

11.1.3 Amgen Inc. Long-acting G-CSF Introduction

11.1.4 Amgen Inc. Revenue in Long-acting G-CSF Business (2020-2025)

11.1.5 Amgen Inc. Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Details

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Long-acting G-CSF Introduction

11.2.4 Pfizer Revenue in Long-acting G-CSF Business (2020-2025)

11.2.5 Pfizer Recent Development

11.3 Sandoz (Novartis)

11.3.1 Sandoz (Novartis) Company Details

11.3.2 Sandoz (Novartis) Business Overview

11.3.3 Sandoz (Novartis) Long-acting G-CSF Introduction

11.3.4 Sandoz (Novartis) Revenue in Long-acting G-CSF Business (2020-2025)

11.3.5 Sandoz (Novartis) Recent Development

11.4 Biocon Biologics Inc.

11.4.1 Biocon Biologics Inc. Company Details

11.4.2 Biocon Biologics Inc. Business Overview

11.4.3 Biocon Biologics Inc. Long-acting G-CSF Introduction

11.4.4 Biocon Biologics Inc. Revenue in Long-acting G-CSF Business (2020-2025)

11.4.5 Biocon Biologics Inc. Recent Development

11.5 Coherus BioSciences, Inc.

11.5.1 Coherus BioSciences, Inc. Company Details

11.5.2 Coherus BioSciences, Inc. Business Overview

11.5.3 Coherus BioSciences, Inc. Long-acting G-CSF Introduction

11.5.4 Coherus BioSciences, Inc. Revenue in Long-acting G-CSF Business (2020-2025)

11.5.5 Coherus BioSciences, Inc. Recent Development

11.6 Spectrum Pharmaceuticals

11.6.1 Spectrum Pharmaceuticals Company Details

11.6.2 Spectrum Pharmaceuticals Business Overview

11.6.3 Spectrum Pharmaceuticals Long-acting G-CSF Introduction

11.6.4 Spectrum Pharmaceuticals Revenue in Long-acting G-CSF Business (2020-2025)

11.6.5 Spectrum Pharmaceuticals Recent Development

11.7 Yifan Pharmaceutical

11.7.1 Yifan Pharmaceutical Company Details

11.7.2 Yifan Pharmaceutical Business Overview

11.7.3 Yifan Pharmaceutical Long-acting G-CSF Introduction

11.7.4 Yifan Pharmaceutical Revenue in Long-acting G-CSF Business (2020-2025)

11.7.5 Yifan Pharmaceutical Recent Development

11.8 CSPC

11.8.1 CSPC Company Details

11.8.2 CSPC Business Overview

11.8.3 CSPC Long-acting G-CSF Introduction

11.8.4 CSPC Revenue in Long-acting G-CSF Business (2020-2025)

11.8.5 CSPC Recent Development

11.9 Jiangsu Hengrui Medicine

11.9.1 Jiangsu Hengrui Medicine Company Details

11.9.2 Jiangsu Hengrui Medicine Business Overview

11.9.3 Jiangsu Hengrui Medicine Long-acting G-CSF Introduction

11.9.4 Jiangsu Hengrui Medicine Revenue in Long-acting G-CSF Business (2020-2025)

11.9.5 Jiangsu Hengrui Medicine Recent Development

11.10 Qilu Pharmaceutical

11.10.1 Qilu Pharmaceutical Company Details

11.10.2 Qilu Pharmaceutical Business Overview

11.10.3 Qilu Pharmaceutical Long-acting G-CSF Introduction

11.10.4 Qilu Pharmaceutical Revenue in Long-acting G-CSF Business (2020-2025)

11.10.5 Qilu Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Amgen Inc

Sandoz(Novartis)

Biocon Biologics Inc

Spectrum Pharmaceuticals

Yifan Pharmaceutical

CSPC

Jiangsu Hengrui Medicine

Qilu Pharmaceutical

List of Tables

Table 1. Global Long-acting G-CSF Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Pegfilgrastim

Table 3. Key Players of Filgrastim Biosimilar

Table 4. Key Players of Others

Table 5. Global Long-acting G-CSF Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Long-acting G-CSF Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Long-acting G-CSF Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Long-acting G-CSF Market Share by Region (2020-2025)

Table 9. Global Long-acting G-CSF Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Long-acting G-CSF Market Share by Region (2026-2031)

Table 11. Long-acting G-CSF Market Trends

Table 12. Long-acting G-CSF Market Drivers

Table 13. Long-acting G-CSF Market Challenges

Table 14. Long-acting G-CSF Market Restraints

Table 15. Global Long-acting G-CSF Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Long-acting G-CSF Market Share by Players (2020-2025)

Table 17. Global Top Long-acting G-CSF Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting G-CSF as of 2024)

Table 18. Ranking of Global Top Long-acting G-CSF Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Long-acting G-CSF Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Long-acting G-CSF, Headquarters and Area Served

Table 21. Global Key Players of Long-acting G-CSF, Product and Application

Table 22. Global Key Players of Long-acting G-CSF, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Long-acting G-CSF Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Long-acting G-CSF Revenue Market Share by Type (2020-2025)

Table 26. Global Long-acting G-CSF Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Long-acting G-CSF Revenue Market Share by Type (2026-2031)

Table 28. Global Long-acting G-CSF Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Long-acting G-CSF Revenue Market Share by Application (2020-2025)

Table 30. Global Long-acting G-CSF Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Long-acting G-CSF Revenue Market Share by Application (2026-2031)

Table 32. North America Long-acting G-CSF Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Long-acting G-CSF Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Long-acting G-CSF Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Long-acting G-CSF Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Long-acting G-CSF Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Long-acting G-CSF Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Long-acting G-CSF Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Long-acting G-CSF Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Long-acting G-CSF Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Long-acting G-CSF Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Long-acting G-CSF Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Long-acting G-CSF Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Long-acting G-CSF Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Long-acting G-CSF Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Long-acting G-CSF Market Size by Country (2026-2031) & (US$ Million)

Table 47. Amgen Inc. Company Details

Table 48. Amgen Inc. Business Overview

Table 49. Amgen Inc. Long-acting G-CSF Product

Table 50. Amgen Inc. Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 51. Amgen Inc. Recent Development

Table 52. Pfizer Company Details

Table 53. Pfizer Business Overview

Table 54. Pfizer Long-acting G-CSF Product

Table 55. Pfizer Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 56. Pfizer Recent Development

Table 57. Sandoz (Novartis) Company Details

Table 58. Sandoz (Novartis) Business Overview

Table 59. Sandoz (Novartis) Long-acting G-CSF Product

Table 60. Sandoz (Novartis) Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 61. Sandoz (Novartis) Recent Development

Table 62. Biocon Biologics Inc. Company Details

Table 63. Biocon Biologics Inc. Business Overview

Table 64. Biocon Biologics Inc. Long-acting G-CSF Product

Table 65. Biocon Biologics Inc. Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 66. Biocon Biologics Inc. Recent Development

Table 67. Coherus BioSciences, Inc. Company Details

Table 68. Coherus BioSciences, Inc. Business Overview

Table 69. Coherus BioSciences, Inc. Long-acting G-CSF Product

Table 70. Coherus BioSciences, Inc. Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 71. Coherus BioSciences, Inc. Recent Development

Table 72. Spectrum Pharmaceuticals Company Details

Table 73. Spectrum Pharmaceuticals Business Overview

Table 74. Spectrum Pharmaceuticals Long-acting G-CSF Product

Table 75. Spectrum Pharmaceuticals Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 76. Spectrum Pharmaceuticals Recent Development

Table 77. Yifan Pharmaceutical Company Details

Table 78. Yifan Pharmaceutical Business Overview

Table 79. Yifan Pharmaceutical Long-acting G-CSF Product

Table 80. Yifan Pharmaceutical Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 81. Yifan Pharmaceutical Recent Development

Table 82. CSPC Company Details

Table 83. CSPC Business Overview

Table 84. CSPC Long-acting G-CSF Product

Table 85. CSPC Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 86. CSPC Recent Development

Table 87. Jiangsu Hengrui Medicine Company Details

Table 88. Jiangsu Hengrui Medicine Business Overview

Table 89. Jiangsu Hengrui Medicine Long-acting G-CSF Product

Table 90. Jiangsu Hengrui Medicine Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 91. Jiangsu Hengrui Medicine Recent Development

Table 92. Qilu Pharmaceutical Company Details

Table 93. Qilu Pharmaceutical Business Overview

Table 94. Qilu Pharmaceutical Long-acting G-CSF Product

Table 95. Qilu Pharmaceutical Revenue in Long-acting G-CSF Business (2020-2025) & (US$ Million)

Table 96. Qilu Pharmaceutical Recent Development

Table 97. Research Programs/Design for This Report

Table 98. Key Data Information from Secondary Sources

Table 99. Key Data Information from Primary Sources

Table 100. Authors List of This Report

List of Figures

Figure 1. Long-acting G-CSF Picture

Figure 2. Global Long-acting G-CSF Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Long-acting G-CSF Market Share by Type: 2024 VS 2031

Figure 4. Pegfilgrastim Features

Figure 5. Filgrastim Biosimilar Features

Figure 6. Others Features

Figure 7. Global Long-acting G-CSF Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Long-acting G-CSF Market Share by Application: 2024 VS 2031

Figure 9. Neoplastic Diseases Case Studies

Figure 10. Blood Disorders Case Studies

Figure 11. Others Case Studies

Figure 12. Long-acting G-CSF Report Years Considered

Figure 13. Global Long-acting G-CSF Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Long-acting G-CSF Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Long-acting G-CSF Market Share by Region: 2024 VS 2031

Figure 16. Global Long-acting G-CSF Market Share by Players in 2024

Figure 17. Global Top Long-acting G-CSF Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting G-CSF as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Long-acting G-CSF Revenue in 2024

Figure 19. North America Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Long-acting G-CSF Market Share by Country (2020-2031)

Figure 21. United States Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Long-acting G-CSF Market Share by Country (2020-2031)

Figure 25. Germany Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Long-acting G-CSF Market Share by Region (2020-2031)

Figure 33. China Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Long-acting G-CSF Market Share by Country (2020-2031)

Figure 41. Mexico Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Long-acting G-CSF Market Share by Country (2020-2031)

Figure 45. Turkey Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Long-acting G-CSF Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Amgen Inc. Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 49. Pfizer Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 50. Sandoz (Novartis) Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 51. Biocon Biologics Inc. Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 52. Coherus BioSciences, Inc. Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 53. Spectrum Pharmaceuticals Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 54. Yifan Pharmaceutical Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 55. CSPC Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 56. Jiangsu Hengrui Medicine Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 57. Qilu Pharmaceutical Revenue Growth Rate in Long-acting G-CSF Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions